Herceptin

Herceptin is a prescription medication whose active ingredient is trastuzumab, supplied as a solution for infusion. It is a monoclonal antibody classified as an antineoplastic agent and is marketed in the European Union. The product is administered intravenously and is indicated for HER2‑positive cancers. Herceptin targets the HER2 receptor on tumor cells, providing a targeted therapeutic approach in oncology. It is used under medical supervision and requires monitoring for infusion‑related reactions.

Herceptin is indicated for several HER2‑positive malignancies, typically as part of combination regimens.

- HER2‑positive metastatic breast cancer, often combined with chemotherapy. - HER2‑positive early breast cancer in the adjuvant setting, following surgery. - HER2‑positive gastric or gastroesophageal junction adenocarcinoma, in combination with chemotherapy. - HER2‑positive metastatic gastric cancer when other therapies are appropriate. - Investigational use in other HER2‑expressing tumors under clinical study.

Herceptin may cause a spectrum of adverse reactions, from mild infusion‑related symptoms to potentially life‑threatening events, and the frequency varies among patients.

Common: - Infusion‑related reactions such as fever, chills, nausea, flushing, or rigors. - Fatigue, asthenia, or general weakness. - Diarrhea, abdominal cramping, or mild gastrointestinal upset. - Headache, dizziness, or transient visual disturbances. - Mild rash, skin erythema, or pruritus; occasional transient elevation of liver enzymes.

Serious: - Cardiac dysfunction, including reduced left ventricular ejection fraction or congestive heart failure. - Severe hypersensitivity reactions, including anaphylaxis and bronchospasm. - Pulmonary toxicity such as interstitial pneumonitis or acute respiratory distress.

When prescribing Herceptin, clinicians should evaluate patient history and monitor specific clinical parameters to reduce risk of complications.

- Baseline and periodic assessment of cardiac function (e.g., echocardiogram or MUGA scan). - Avoid use in patients with uncontrolled cardiac disease or recent myocardial infarction. - Monitor for signs of infusion reactions; premedication with antihistamines and corticosteroids may be recommended. - Assess liver function tests before each infusion and adjust if significant elevations occur. - Use caution in pregnant or breastfeeding women; the drug may cross the placenta and its safety is not established. - Evaluate for potential drug interactions, especially with cardiotoxic agents.

Herceptin can interact with other medicines, influencing its safety profile or therapeutic effectiveness.

Avoid: - Concurrent use with other HER2‑targeted monoclonal antibodies (e.g., pertuzumab) without appropriate clinical justification, due to overlapping toxicity. - Co‑administration with cardiotoxic chemotherapeutics (e.g., anthracyclines) in the same cycle, which may increase cardiac risk.

Use with caution: - Concomitant use of live vaccines, as immune modulation may affect vaccine efficacy. - Combination with drugs that prolong QT interval, requiring cardiac monitoring. - Concurrent administration of strong CYP3A4 inducers or inhibitors is not expected to affect trastuzumab significantly, but clinical judgment is advised.